Incidence and survival patterns of cutaneous T-cell lymphomas in the United States

Incidence and survival patterns of cutaneous T-cell lymphomas in the United States
复制标题

DOI:
10.3109/10428194.2012.729831
复制
发表时间:
2013-04-01
影响因子:
2.6
通讯作者:
Lechowicz, Mary Jo
Lechowicz, Mary Jo
中科院分区:
医学4区
文献类型:
--
作者:
Imam, Muhammad Hassaan;Shenoy, Pareen J.;Lechowicz, Mary Jo

文献摘要

被引文献

相似文献

使用美国监测,流行病学和最终结果(SEER)17数据集,我们检查了根据世界卫生组织-欧洲癌症研究和治疗组织(WHO-EORTC)分类诊断的皮肤T细胞淋巴瘤(CTCL)患者的发病率和生存模式。2005 ~ 2008年共确诊CTCL 2273例。蕈样肉芽肿(MF)的年龄校正发病率为每10万人年0.55,Sezary综合征(SS)为每10万人年0.01。男性(MF/SS男性与女性的发病率比[IRR] 1.57)和黑人患者(MF黑人与白色IRR 1.55)的发病率较高。黑人CTCL患者在较年轻时被诊断,而黑人MF/SS患者表现为晚期,生存率低于白色患者。在多变量Cox回归模型中,年龄>60岁(风险比[HR] 4.78,95%置信区间[CI] 2.97-7.70),黑人(HR 2.09,95% CI 1.29-3.37)和晚期(HR 6.06,95% CI 3.66-10.05)预测MF/SS患者的生存率较差。为了更好地了解这些疾病和治疗CTCL的新策略,有必要进行更多的研究来确定这些差异的原因。
Using the United States Surveillance, Epidemiology and End Results (SEER) 17 dataset, we examined incidence and survival patterns for patients with cutaneous T-cell lymphomas (CTCLs) diagnosed following institution of the World Health Organization-European Organisation for Research and Treatment of Cancer (WHO-EORTC) classification. From 2005 to 2008, 2273 cases of CTCL were diagnosed. The age-adjusted incidence rate per 100 000 person-years for mycosis fungoides (MF) was 0.55 and for Sezary syndrome (SS) was 0.01. Incidence was higher among males (MF/SS male-to-female incidence rate ratio [IRR] 1.57) and black patients (MF black-to-white IRR 1.55). Black patients with CTCL were diagnosed at a younger age and black patients with MF/SS presented with advanced stage and had worse survival than white patients. In multiple-variable Cox-regression models, age >60 (hazard ratio [HR] 4.78, 95% confidence interval [CI] 2.97-7.70), black race (HR 2.09, 95% CI 1.29-3.37) and advanced stage (HR 6.06, 95% CI 3.66-10.05) predicted worse survival for patients with MF/SS. Additional research identifying reasons for these differences are necessary to better understand these diseases and for new strategies in the treatment of CTCL.